- Registry of Biological/Targeted Therapy BIOREP - Summary Report 20192020 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine, Central Library of Charles University
- Registry of Biological/Targeted Therapy BIOREP - Summary Report 20202021 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine
- Atopic Dermatitis in the BIOREP Registry2021 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine, Central Library of Charles University
- BIOREP - Biologic/Targeted Therapy Registry: 2022 Summary Report2023 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine, Central Library of Charles University
- Registry of Biological/Targeted Therapy BIOREP - Summary Report 20212022 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine, Central Library of Charles University
- Efficacy of biological treatment of moderate to severe psoriasis - analysis from the BIOREP Registry2021 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine, Central Library of Charles University
- Analysis of Patients with Moderate to Severe Psoriasis before Starting Biologic Therapy in the Czech Republic - Data from BIOREP Registry 2005 - 20162016 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine
- BIOREP - registr pro biologickou léčbu psoriázy v České republice2017 | First Faculty of Medicine
- Dupilumab for the treatment of atopic dermatitis: Real-world data from the Czech Republic BIOREP registry2022 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine, Central Library of Charles University
- Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry2023 | First Faculty of Medicine, Third Faculty of Medicine
- Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry2022 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine, Central Library of Charles University
- Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries2017 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine
- Léčba psoriázy2015 | Third Faculty of Medicine
- Efficacy of switches within the class of IL-17 inhibitors: An analysis of data from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy (BIOREP)2022 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine, Central Library of Charles University
- Real-World Evidence From More Than 1000 Patients Treated With Adalimumab For Moderate-to-Severe Psoriasis in the Czech Republic2021 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine
- Demographic data, comorbidities, quality of life, and survival probability of biologic therapy associated with sex-specific differences in psoriasis in the Czech Republic2021 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine
- Employing Adalimumab in Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Real-Life Multicenter Data from the Czech Republic2023 | First Faculty of Medicine, Third Faculty of Medicine